Form 4: Amgen Executive Murdo Gordon Sells 8,771 Shares of Common Stock

EVP Murdo Gordon reports the sale of 8,771 Amgen shares at an average price of $294.7947 on February 11, 2025.

Summary

• On February 11, 2025, Murdo Gordon, EVP, Global Commercial Operations at Amgen Inc., sold 8,771 shares of Amgen common stock.
• The sale was executed at an average price of $294.7947 per share.
• Following the transaction, Gordon directly owns 44,186 shares of Amgen common stock, which includes 773 Dividend Equivalents (DEs).
• The prices for the sale ranged from $294.6101 to $294.885 per share.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating a routine stock sale by an executive. It doesn't inherently convey positive or negative sentiment about the company's performance.

Industry Context

Executive stock sales are a common occurrence in publicly traded companies and are often related to personal financial planning. The sale itself doesn't necessarily indicate a negative outlook on the company.

Comparison to Industry Standards

• Executive stock sales are a normal part of compensation and portfolio management at companies like Amgen, which can be compared to similar large-cap biotechnology firms such as Gilead Sciences (GILD) or Biogen (BIIB).
• These companies' executives also periodically report stock transactions via SEC Form 4 filings.
• The scale of the sale is relatively small compared to the overall market capitalization of Amgen.

Stakeholder Impact

• The sale of shares by an executive could have a minor impact on shareholder sentiment, but is unlikely to have a significant effect on the company's operations or financial performance.

Key Dates

Keywords

Amgen, Murdo Gordon, SEC Form 4, Stock Sale, Executive, AMGN, Dividend Equivalents